Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice

Area of Science:

• Nephrology
• Bone Metabolism
• Pharmacology

Background:

• The Kidney Disease Outcomes Quality Initiative (K/DOQI) provides guidelines for managing bone metabolism in chronic kidney disease (CKD).
• These guidelines recommend limiting calcium-based phosphate binders (CBPBs) and adjusting their use based on serum calcium and parathyroid hormone levels.
• Adherence to these recommendations is crucial for preventing complications in CKD patients.

Purpose of the Study:

• To evaluate the clinical practice patterns of calcium-based phosphate binder (CBPB) use in patients with chronic kidney disease.
• To assess the consistency of CBPB usage with K/DOQI clinical practice guidelines.

Main Methods:

• A retrospective review of 283 patients across three hemodialysis units was conducted.
• Data on intact parathyroid hormone, blood chemistries, and the use of CBPBs, vitamin D, and cinacalcet were collected.
• CBPB use was classified as consistent or inconsistent with K/DOQI guidelines based on patient data.

Main Results:

• Calcium-based phosphate binders (CBPBs) were used in 61% of the reviewed patients.
• Doses exceeded recommended limits in 10% of patients, and CBPBs were not adjusted appropriately in cases of elevated serum calcium or low parathyroid hormone levels.
• Overall, 29% of patients receiving CBPBs did so inconsistently with K/DOQI guidelines.

Conclusions:

• A significant proportion of chronic kidney disease patients treated with CBPBs do not adhere to K/DOQI guidelines.
• Reasons for this inconsistency may include physician disagreement with guidelines, lack of awareness, or patient-specific factors.
• Further investigation is needed to understand and address the barriers to guideline adherence in clinical practice.